Genitope Corp. revealed that cancer vaccine MyVax missed its primary endpoint in a pivotal Phase III trial, failing to improve progression-free survival compared to control in patients with follicular B-cell non-Hodgkin's lymphoma (NHL). (BioWorld Today)